Login to Your Account



Washington Roundup


Thursday, September 12, 2013
A new analysis from the Tufts Center for the Study of Drug Development (CSDD) showed that while lack of commercial viability is the leading cause of Phase I failures for new drug candidates, efficacy issues lead as the reason behind Phase II failures.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription